Sugi Predict

Sugi Predict / Compounds / SCHEMBL369993

SCHEMBL369993

SCHEMBL369993

CCCCCCC(CCCCCC)(CCCCC(CCCCCC)(CCCCCC)C(CCCCCC)(CCCCCC)CCCCCC)C(=O)OCC

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 2/20 0.56
▸ CYP4A11 Q02928 2/20 0.56
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ MAPT P10636 1/20 0.54
▸ ATM Q13315 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ HTT P42858 1/20 0.46
▸ THRB P10828 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ CES2 O00748 1/20 0.39
▸ NAAA Q02083 1/20 0.37
▸ DGKA P23743 1/20 0.37
▸ GGPS1 O95749 1/20 0.37
▸ SMPD1 P17405 1/20 0.37
▸ PPARG P37231 1/20 0.37
▸ PPARA Q07869 1/20 0.37
▸ FAAH O00519 2/20 0.37
▸ FDPS P14324 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7745435 1.00 CYP4F2 (0.56) CYP4F2CYP4A11MEN1KMT2AMAPT
Acetic Acid SCHEMBL2703066 0.95 MEN1 (0.54) CYP4F2CYP4A11MEN1KMT2AMAPT
Acetic Acid SCHEMBL761529 0.95 MEN1 (0.54) CYP4F2CYP4A11MEN1KMT2AMAPT
Acetic Acid SCHEMBL10862085 0.95 MEN1 (0.54) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL717168 0.94 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL28984795 0.94 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL718008 0.94 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL169939 0.94 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL10871818 0.94 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL87652 0.94 CYP4F2 (0.61) CYP4F2CYP4A11MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116396302-B Indole compound and preparation method thereof 南京工业大学 2024-07-05 — — CN disclosed
CN-115515956-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-25 — — CN disclosed
CN-115461334-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-21 — — CN disclosed
US-20240166627-A1 Terpyridinedione compound or salt thereof, and preparation method and application thereof SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2024-05-23 — — US disclosed
CN-117903094-A Process for preparing alpha-pyrone-polyketone 深圳乾延药物研发科技有限公司 2024-04-19 — — CN disclosed
CN-116648244-B Terpyridyl dione compound or salt thereof, and preparation method and application thereof 深圳信立泰药业股份有限公司 2023-12-15 — — CN disclosed
CN-114728917-B Oxamide derivative, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-12-08 — — CN disclosed
EP-4242202-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) 2023-09-13 — — EP disclosed
CN-111620910-B Metal complex and application thereof 广东阿格蕾雅光电材料有限公司 2023-09-05 — — CN disclosed
CN-116648244-A Terpyridyl dione compound or salt thereof, and preparation method and application thereof 深圳信立泰药业股份有限公司 2023-08-25 — — CN disclosed
EP-0659735-A1 PROCESS FOR PRODUCING ANILINE DERIVATIVE SAGAMI CHEMICAL RESEARCH CENTER (JP) 1995-06-28 — — EP disclosed
US-5403814-A Preemergence and postemergence herbicides CIBA-GEIGY CORPORATION (US) 1995-04-04 — — US disclosed
EP-0638557-A1 N-phenylpyri(mi)dine-N'-phenyl-urea derivatives, their preparation and their use as ACAT inhibitors NIHON NOHYAKU CO., LTD. (JP) 1995-02-15 — — EP disclosed
EP-0635485-A1 TETRAHYDROPHTHALAMIDE DERIVATIVE, INTERMEDIATE FOR PRODUCING THE SAME, PRODUCTION OF BOTH, AND HERBICIDE CONTAINING THE SAME AS ACTIVE INGREDIENT SAGAMI CHEMICAL RESEARCH CENTER (JP) 1995-01-25 — — EP disclosed
EP-0601486-A1 Cis-epoxide derivatives useful as irreversible HIV protease inhibitors and process and intermediates for their preparation LUCKY LTD. (KR) 1994-06-15 — — EP disclosed
CN-1084847-A Tetrahydrochysene butyl benzene orthobenzol diacid amide derivative and its preparation intermediate and manufacture method thereof and with its weedicide as effective constituent SAGAMI CHEM RES (JP) 1994-04-06 — — CN disclosed
US-5288727-A Hydrazone compounds, processes for their production, intermediates useful for their production and pesticidal compositions containing them ISHIHARA SANGYO KAISHA LTD. (JP) 1994-02-22 — — US disclosed
EP-0540697-A1 NOVEL SULFONYLUREAS Novartis AG (CH) 1993-05-12 — — EP disclosed
WO-1992016522-A1 NOVEL SULFONYLUREAS CIBA-GEIGY AG (CH) 1992-10-01 — — WO disclosed
EP-0500111-A2 Hydrazone compounds, processes for their production, intermediates useful for their production and pesticidal compositions containing them ISHIHARA SANGYO KAISHA, LTD. (JP) 1992-08-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166627-A1 Terpyridinedione compound or salt thereof, and preparation method and application thereof TNF, MAPKAPK2, MAPK1 CYP4F2 536/4885CYP4A11 378/4885MEN1 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.